Ali Ameena, Fossas De Mello Natalia, Luo Yonghong, Bensreti Husam, Melynk Samuel, Shaver Joseph C, Choudhary Vivek, McGee-Lawrence Meghan E, Bollag Wendy B
Department of Physiology, Medical College of Georgia at Augusta University, Augusta, GA 30912, USA.
Department of Cellular Biology and Anatomy, Medical College of Georgia at Augusta University, Augusta, GA 30912, USA.
Int J Mol Sci. 2025 Aug 28;26(17):8346. doi: 10.3390/ijms26178346.
The glucocorticoid receptor (GR) and mineralocorticoid receptor (MR) are ligand-activated transcription factors that regulate epidermal homeostasis, inflammation, and function. Prior studies using epidermal-specific conditional single and double knockout mice have shown their importance in skin physiology; however, clinically human disease is largely treated pharmacologically. Our objective was to examine how systemic MR/GR antagonism affects cutaneous gene expression and epidermal thickness in aged (18-month-old) C57BL/6J female mice. Mice were treated with selective GR (relacorilant), selective MR (eplerenone), or dual GR/MR (miricorilant) antagonists for 8 weeks. Quantitative RT-qPCR analysis of the skin showed that miricorilant significantly upregulated Sgk1, a GR/MR target. Miricorilant also increased the expression of keratinocyte differentiation markers and downregulated key inflammatory cytokines and Col3a1, a collagen subtype associated with tissue remodeling. Relacorilant suppressed Scnn1g, a subunit of the epithelial sodium channel. None of the antagonists significantly altered proliferation markers, epidermal thickness, or regulators of glucocorticoid activity. Our findings show that miricorilant downregulated inflammatory cytokines and increased differentiation marker expression without affecting epidermal thickness, suggesting its potential to treat inflammatory skin diseases. The results contrast with data from GR/MR knockout studies, highlighting the likely significance of receptor dynamics. Further studies of antagonist effects on receptor interactions with co-regulators appear warranted.
糖皮质激素受体(GR)和盐皮质激素受体(MR)是配体激活的转录因子,可调节表皮稳态、炎症和功能。先前使用表皮特异性条件性单敲除和双敲除小鼠的研究已表明它们在皮肤生理学中的重要性;然而,在临床上人类疾病大多采用药物治疗。我们的目的是研究全身性MR/GR拮抗作用如何影响老年(18个月大)C57BL/6J雌性小鼠的皮肤基因表达和表皮厚度。小鼠用选择性GR拮抗剂(relacorilant)、选择性MR拮抗剂(依普利酮)或双GR/MR拮抗剂(miricorilant)治疗8周。对皮肤进行的定量RT-qPCR分析表明,miricorilant显著上调了GR/MR靶基因Sgk1。Miricorilant还增加了角质形成细胞分化标志物的表达,并下调了关键炎症细胞因子和与组织重塑相关的胶原亚型Col3a1。Relacorilant抑制了上皮钠通道的一个亚基Scnn1g。这些拮抗剂均未显著改变增殖标志物、表皮厚度或糖皮质激素活性调节剂。我们的研究结果表明,miricorilant下调了炎症细胞因子并增加了分化标志物的表达,而不影响表皮厚度,提示其治疗炎症性皮肤病的潜力。这些结果与GR/MR敲除研究的数据形成对比,突出了受体动态变化的可能重要性。似乎有必要进一步研究拮抗剂对受体与共调节因子相互作用的影响。